Navigation Links
bioRASI Completes Acquisition of Ukrainian CRO
Date:3/28/2013

Aventura, FL (PRWEB) March 28, 2013

bioRASI, a full service, global Contract Research Organization (CRO), announced today that it has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.

“We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure,” explained Dr. Boris Reznik, Chairman of bioRASI. “This acquisition enhances bioRASI’s global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs.”

The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI’s already commanding presence throughout Eastern Europe.

“While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI,” explained Dr. Veklych, SCRG’s Executive Director. “An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI’s winning team.”    

About bioRASI
bioRASI is an award-winning Full Service Global CRO providing clinical development services that optimize its sponsors’ scientific, clinical, and business results. bioRASI facilitates obtaining global marketing approval for drugs, biotherapeutics, and medical devices by delivering high quality regulatory and clinical strategies, so
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Novira Therapeutics Completes $25 Million Series A Financing
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Amarantus Completes Name Change and CUSIP Change
4. Advanced Cell Diagnostics Completes $12 Million Series B Financing
5. Synthetic Biologics Completes $10.8 Million Private Placement Financing
6. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
7. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
8. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
9. China Integrated Energy Inc. Completes Independent Investigation
10. Oxford Finance Completes $271.4 Million Securitization Transaction
11. inVentiv Health Completes Acquisition of Kforce Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Deerfield Management Company, L.P. today ... L.P., which will invest in groundbreaking advancements in science ... cancer, and orphan diseases. The venture capital fund will ... are developed and improve the way healthcare is delivered ... largest healthcare-focused venture funds in the sector, will donate ...
(Date:7/28/2015)... 2015 BioStructures, LLC, a privately held ... milestone of 4,000 implantations of Signafuse® Bioactive Bone ... early 2014 as a bone void filler indicated ... This is a distinguished status among recently cleared ... new synthetic products have received clearance with a ...
(Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2
... ALISO VIEJO, Calif., May 5 ... Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership ... abnormalities that are associated with over 270 genetic syndromes ... whole genome and mitochondrial array. The partnership with ...
... NEEDHAM, Mass., May 5 A new ... to improve both building systems performance and energy ... with much of the savings linked to low-cost modifications. ... Engineering, Inc. (EH&E), a leading Massachusetts-based environmental and ...
... HUBBARD, Ohio, May 5 NanoLogix, Inc. (Pink Sheets: ... technology at booth 749 during the 109th Annual ASM ... in Philadelphia May 17th - 21st. The ASM meeting ... NanoLogix will be Dr. Sergey Gazenko and CEO Bret ...
Cached Biology Technology:Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine 2New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... A major challenge for cancer biologists is figuring out which ... cell are most important for driving the cancer,s spread. ... have now pinpointed a gene that appears to drive progression ... cancer accounting for about 15 percent of lung cancer cases. ...
... Richmond and Providence cities scattered across the eastern ... common, all have coal-fired power plants. A new study ... Indianapolis is among the first to investigate mercury deposits ... The study, which appears in the July 2011 ...
... & Melinda Gates Foundation has awarded Delft University of Technology ... Aim of this project is to develop new technology for ... lines, and at costs affordable to the poor in developing ... this grant today at the AfricaSan conference in Rwanda (www.africasan3.com) ...
Cached Biology News:New lung-cancer gene found 2Soil samples reveal urban mercury footprints 2Reinventing the toilet for safe and affordable sanitation 2
Component in MasterPure™ Purification Kits...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
...
... Signets FAST RED Chromogen ... chromogen,tablets and substrate buffer. FAST ... of alkaline phosphatase to produce ... noise. The ...
Biology Products: